NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow NEO
NeoGenomics, Inc. (NEO) EV/Sales
As of 16 October 2026, NeoGenomics, Inc. (NEO) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 1.4× (July 2025) to 14.4× (December 2020); the current reading is higher than 39% of that period. That is below the Diagnostics & Research industry median of 5.5× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | (23.43%) |
| FY2024 | 3.4× | (5.78%) |
| FY2023 | 3.6× | 48.82% |
| FY2022 | 2.4× | (71.54%) |
| FY2021 | 8.5× | (34.01%) |
| FY2020 | 12.9× | 83.82% |
| FY2019 | 7.0× | 64.98% |
| FY2018 | 4.2× | 30.87% |
| FY2017 | 3.2× | (0.71%) |
| FY2016 | 3.3× | (37.22%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | 66.97% |
| Mar 2026 | 1.8× | (30.06%) |
| Dec 2025 | 2.6× | 34.51% |
| Sep 2025 | 1.9× | 1.33% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 2.0× |
| NEO NeoGenomics, Inc. | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| PSNL Personalis, Inc. compare | 20.9× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)